Lartruvo Phase III Fail Rocks Lilly Oncology Plans
It looks like the end for Latruvo after a late-stage trial in soft tissue sarcoma patients did not confirm the overall survival benefit seen in the Phase II study that saw the Lilly drug get a speedy approval from the FDA and the EMA in 2016.
You may also be interested in...
Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.
Delegates at this year’s ASCO meeting in Chicago will hear late-breaking clinical data for a number of studies from AstraZeneca, Novartis, Pfizer, Astellas, Merck & Co and Seattle Genetics which are set to shake up their respective markets. There will also be more clarity on where Lilly’s Lartruvo went so wrong.
The latest drug development news and highlights from our US FDA Performance Tracker.